These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33263751)

  • 1. Forget polypharmacy for type 2 diabetes! Weight management is a better investment.
    Lean M; McCombie L; Xin Y
    Nephrol Dial Transplant; 2022 Apr; 37(5):844-846. PubMed ID: 33263751
    [No Abstract]   [Full Text] [Related]  

  • 2. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department.
    Dobrică EC; Găman MA; Cozma MA; Bratu OG; Pantea Stoian A; Diaconu CC
    Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31382651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cost of polypharmacy in patients with type 2 diabetes mellitus].
    García A LM; Villarreal R E; Galicia R L; Martínez G L; Vargas D ER
    Rev Med Chil; 2015 May; 143(5):606-11. PubMed ID: 26203572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment.
    Noale M; Veronese N; Cavallo Perin P; Pilotto A; Tiengo A; Crepaldi G; Maggi S
    Acta Diabetol; 2016 Apr; 53(2):323-30. PubMed ID: 26155958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic medications and polypharmacy.
    Peron EP; Ogbonna KC; Donohoe KL
    Clin Geriatr Med; 2015 Feb; 31(1):17-27, vii. PubMed ID: 25453298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
    Vernino S; Claassen D
    Clin Auton Res; 2017 Jul; 27(Suppl 1):33-34. PubMed ID: 28674868
    [No Abstract]   [Full Text] [Related]  

  • 7. [The UK Prospective Diabetes Study. Polypharmacy marching in?].
    Hilsted JC
    Ugeskr Laeger; 1999 Aug; 161(35):4884. PubMed ID: 10778319
    [No Abstract]   [Full Text] [Related]  

  • 8. Polypharmacy among people living with type 2 diabetes mellitus in rural communes in Vietnam.
    Thi Bui DH; Nguyen BX; Truong DC; Meyrowitsch DW; Søndergaard J; Gammeltoft T; Bygbjerg IC; Jannie N
    PLoS One; 2021; 16(4):e0249849. PubMed ID: 33831073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypharmacy and combination therapy in the management of hypertension in elderly patients with co-morbid diabetes mellitus.
    Munger MA
    Drugs Aging; 2010 Nov; 27(11):871-83. PubMed ID: 20964461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of drugs in the management of diabetes mellitus.
    Das S
    J Indian Med Assoc; 2002 Jul; 100(7):434, 436, 445-7. PubMed ID: 12674168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort.
    van Oort S; Rutters F; Warlé-van Herwaarden MF; Schram MT; Stehouwer CD; Tack CJ; Abbink EJ; Wolffenbuttel BH; van der Klauw MM; DeVries JH; Siegelaar SE; Sijbrands EJ; Özcan B; de Valk HW; Silvius B; Schroijen MA; Jazet IM; van Ballegooijen AJ; Beulens JWJ; Elders PJ; Kramers C;
    Diabet Med; 2021 Apr; 38(4):e14406. PubMed ID: 32961611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines--a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems.
    Bauer S; Nauck MA
    Diabet Med; 2014 Sep; 31(9):1078-85. PubMed ID: 24824448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pharmacist intervention on polypharmacy in patients with type 2 diabetes in Japan.
    Horii T; Atsuda K
    BMC Res Notes; 2020 Mar; 13(1):183. PubMed ID: 32228686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polypharmacy reduction potential of cinnamic acids and some related compounds in pre- and post-onset management of type 2 diabetes mellitus.
    Barre DE; Mizier-Barre KA
    Endocr Regul; 2020 Apr; 54(2):137-155. PubMed ID: 32597155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
    Tschöp MH; Finan B; Clemmensen C; Gelfanov V; Perez-Tilve D; Müller TD; DiMarchi RD
    Cell Metab; 2016 Jul; 24(1):51-62. PubMed ID: 27411008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life.
    Al-Musawe L; Torre C; Guerreiro JP; Rodrigues AT; Raposo JF; Mota-Filipe H; Martins AP
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00621. PubMed ID: 32618136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?].
    Pedersen OB; Gaede PH
    Ugeskr Laeger; 2000 Jun; 162(25):3582-91. PubMed ID: 11016281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lignans' Potential in Pre and Post-onset Type 2 Diabetes Management.
    Barre DE; Mizier-Barre KA
    Curr Diabetes Rev; 2019; 16(1):2-11. PubMed ID: 30215336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice.
    van Bruggen R; Gorter K; Stolk RP; Zuithoff P; Klungel OH; Rutten GE
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):983-91. PubMed ID: 19623570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediterranean diet, walking outdoors and polypharmacy in older patients with type II diabetes.
    Fortes C; Mastroeni S; Tubili C; Gianni S; Pandolfo MM; Fano V
    Eur J Public Health; 2021 Oct; 31(4):829-835. PubMed ID: 34499712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.